Ahmed El-Modir (@elmodir) profile picture
Birmingham/UK
Joined August 2009
Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)Photo by Ahmed El-Modir (@elmodir)
Ahmed El-Modir retweeted
🚨 55.6% response rate in heavily pretreated ovarian cancer! Could Rinatabart sesutecan (Rina-S) be the next major ADC in gynecologic oncology? 📌 RAINFOL-01 | Phase 1/2 | IJGC 2026 An FRα-directed ADC carrying an exatecan payload, evaluated without FRα-based patient selection. 🔹 Ovarian cancer (120 mg/m²) • ORR: 55.6%, including 4 complete responses • Median DoR: Not reached 🔹 Endometrial cancer • ORR: 50% (100 mg/m²) • ORR: 44.1% (120 mg/m²) • Median DoR: 9.8–13.5 months ⚠️ Significant grade ≥3 cytopenias, particularly neutropenia and anemia. 💡 My take: Promising activity across FRα expression levels, but small, noncomparative cohorts. Phase 3 confirmation is essential. @oncoalert #OvarianCancer #EndometrialCancer #ADC Full paper link in comment below ⬇️
1
4
14
1,465
Ahmed El-Modir retweeted
NIAGARA Trial Explores Urinary Tumor DNA as a Biomarker in Bladder Cancer. Urinary tumor DNA in #MIBC from NIAGARA. @MichvdHeijden @NKI_nl joins @ERPlimackMD @FoxChaseCancer to discuss utDNA and ctDNA with perioperative durvalumab. pCR was 72% if utDNA-negative vs 18% if positive. #WatchNow on UroToday > bit.ly/4eCoewi
5
6
876
Ahmed El-Modir retweeted
Cardiovascular Risk Assessment and Management in #ProstateCancer Survivorship. Cardiovascular care is #ProstateCancer survivorship care. @ravi_b_parikh @WinshipAtEmory notes only 68% of VA patients received comprehensive CV risk assessment and outlines a structured approach starting at the ADT conversation. @PCFnews #WatchNow on UroToday > bit.ly/3VJjGhh
2
9
813
Ahmed El-Modir retweeted
ADT Class and Cardiovascular Risk: A Large Retrospective Analysis in Prostate Cancer. Does ADT class affect cardiovascular risk in #ProstateCancer? @OncHahn @UTMDAnderson joins @neerajaiims @DanaFarber to discuss a large real-world analysis of major adverse cardiac events in men receiving androgen deprivation therapy. #WatchNow on UroToday > bit.ly/4ykeNIZ
1
9
16
1,407
Ahmed El-Modir retweeted
#ProstateCancer Highlights and Clinical Implications. @CaPsurvivorship, @DanaFarber, and @zklaassen_md review the DASL-HiCaP, PROTEUS, CAPItello-281, and JNJ-6143 studies from #ESMO26 in this conversation on UroToday > bit.ly/4iwbatD
8
16
1,306
Ahmed El-Modir retweeted
Optimizing Therapy for Locally Advanced #ProstateCancer. Presented by @BarbaraJereczek. #ESMO26 written coverage by @zklaassen_md > bit.ly/4z7fiav #RadOnc #GUOnc @myESMO
15
1
44
3,776
Ahmed El-Modir retweeted
Management of #mCRPC: Personalized Treatment Selection and Sequencing. Presented by Dr. Deborah Mukherji, MBBS, FRCP. #ESMO26 written coverage by @zklaassen_md > bit.ly/4eSjvGU #ProstateCancer #PrecisionOncology @myESMO
16
28
1,413
Ahmed El-Modir retweeted
LuCAB: Phase I/II Trial of Cabazitaxel + 177Lu-PSMA in mCRPC. Presented by @LouiseKostos @PeterMacCC. #ESMO26 written coverage by @rksayyid > bit.ly/4zULptV #ProstateCancer #mCRPC #ClinicalTrials @myESMO
1
8
15
980
Ahmed El-Modir retweeted
Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) nej.md/4BiCvbk #ESMO26 | @myESMO
1
38
5
97
20,752
Ahmed El-Modir retweeted
🚨 PD-L1 ≥50% NSCLC: Is pembrolizumab alone enough? 🔥 PERSEE Phase III | #ESMO26 Pembrolizumab + chemotherapy vs pembrolizumab alone: 📊 PFS: 16.1 vs 6.9 months (HR 0.56; p<0.001) 📊 OS: 50.2 vs 29.9 months (HR 0.77; CI crosses 1) 🎯 PFS benefit persisted even with PD-L1 ≥90%. 💡 Verdict: Strong PFS benefit, but OS advantage remains unproven. @myesmo @ESMO_open @ASCO @oncoalert Full paper link in comment below ⬇️
🚨 PD-L1 ≥50% in NSCLC: Is pembrolizumab alone enough? 🔥 PERSEE Phase III | #ESMO26 Concomitant publication in Annals of Oncology. Pembrolizumab + chemotherapy vs pembrolizumab alone: 📊 PFS: 16.1 vs 6.9 months (HR 0.56) 🎯 ORR: 77.5% vs 50.3% ⚠️ Grade ≥3 toxicity: 54% vs 19% OS: 50.2 vs 29.9 months (HR 0.77), not statistically significant. 💡 Verdict: Better disease control, but at a substantial toxicity cost. Is PD-L1 ≥50% alone sufficient to omit chemotherapy? @ESMO_open @myesmo @ASCO @oncoalert #ESMO26 #LungCancer
6
26
1,358
Ahmed El-Modir retweeted
Original Article: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC (phase 3 OptiTROP-Lung06 trial) nej.md/4Bo3liu #ESMO26 | @myESMO
3
33
3
116
18,537
Ahmed El-Modir retweeted
Original Article: Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer (phase 3 DeLLphi-305 trial) nej.md/4iveIgW #ESMO26 | @myESMO
29
1
91
13,934
Ahmed El-Modir retweeted
ESMO 2026 | TOP 10 LUNG CANCER TRIALS TO WATCH! From DLL3 bispecifics and next-generation KRAS inhibitors to novel ADCs, major lung cancer data are coming at #ESMO26. 🔥 My Top 10 Trials 1.DeLLphi-305 | Tarlatamab + durvalumab | ES-SCLC 2.SAFFRON | Osimertinib + savolitinib | MET-altered EGFR+ NSCLC 3.Krascendo 1 | Divarasib vs approved KRAS G12C inhibitors 4.OptiTROP-Lung06 | Sacituzumab tirumotecan + pembrolizumab | 1L NSCLC 5.OptiTROP-Lung04 | TROP2 ADC after EGFR-TKI progression 6.SigVie-002 | Integrin αvβ6 ADC vs docetaxel 7.SARON | Consolidation RT in oligometastatic NSCLC 8.PERSEE | Pembrolizumab ± chemotherapy | PD-L1 ≥50% 9.DeLLphi-304 | Long-term survival with tarlatamab 10.ASTRIDE | Serplulimab vs atezolizumab + chemotherapy | ES-SCLC Three Presidential presentations deserve special attention: DeLLphi-305, SAFFRON and Krascendo 1. Which trial could have the biggest impact on lung cancer treatment? @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #LungCancer #Oncology
🤖 Made with AI
🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨‍⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open
28
3
95
15,805
Ahmed El-Modir retweeted
Presented at #ESMO26: In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW @myESMO
9
149
32
506
76,786
Ahmed El-Modir retweeted
Surreal footage. Total solar eclipse in Spain.
124
1,418
70
9,774
484,935
Ahmed El-Modir retweeted
Denosumab vs Zoledronic Acid in Bone Metastases • 3 pivotal phase III trials • >5,700 patients in pooled analysis • Modest reduction in skeletal-related events with denosumab (HR 0.83) • No overall survival benefit • More hypocalcemia with denosumab • Less renal toxicity and no dose adjustment Choose based on efficacy, renal function, convenience, cost, and patient preference. #Oncology #MedTwitter #BoneMetastases #BreastCancer #ProstateCancer #MVOnco
18
38
1,713
Ahmed El-Modir retweeted
#ASCO26 Abstract #5501 RUBY trial: Long-term survival rates and cure modeling with dostarlimab + chemotherapy in dMMR/MSI-H endometrial cancer.
2
3
631
Ahmed El-Modir retweeted
Adjuvant RT may finally be back in bladder cancer. The phase III BART trial shows that modern pelvic IMRT after cystectomy significantly improves locoregional control in high-risk MIBC. 🚨 🇮🇳 Multicenter randomized trial 153 patients 90% received perioperative chemotherapy 🩻 Adjuvant RT vs Observation after radical cystectomy 📌 2-year LRFS 87.1% vs 76.0% HR 0.43 (P=.04) 📌 2-year DFS 71.6% vs 58.7% 📌 2-year OS 70.4% vs 57.4% Most striking finding: ❌ No isolated pelvic recurrence after adjuvant RT. Despite historical concerns, toxicity remained low with modern IG-IMRT: ⚠️ Grade ≥3 acute toxicity: <5% ⚠️ No major increase in severe late toxicity This is important because pelvic failures after cystectomy are often devastating and rarely salvageable. The study strongly reopens the discussion around integrating pelvic RT into multimodality care for high-risk bladder cancer, especially in the modern immunotherapy era. Could adjuvant RT + IO become the next frontier in MIBC? 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #BladderCancer #RadOnc @ASCO @myesmo @esmo_o @OncoAlert
3
33
1
72
5,992
Ahmed El-Modir retweeted
🚨 FDA approval: Atezolizumab enters the MRD-guided adjuvant space in MIBC. FDA has approved atezolizumab/Tecentriq Hybreza for adults with muscle-invasive bladder cancer after cystectomy who are ctDNA MRD-positive by an FDA-authorized test. Based on IMvigor011: 🧬 Population: MIBC post-cystectomy + ctDNA MRD+ 💊 Arm: Atezolizumab vs placebo 📉 DFS: 9.9 vs 4.8 months HR 0.64, p=0.0047 📈 OS: 32.8 vs 21.1 months HR 0.59, p=0.0131 Key point: This is not “adjuvant IO for all.” This is MRD-guided escalation after cystectomy. ctDNA is no longer just prognostic. It is becoming treatment-directing. #OncoTwitter #MedTwitter #BladderCancer #UroOnc @FDAOncology @OncoAlert @myESMO @asco @esmo_open
9
1
24
4,135
Ahmed El-Modir retweeted
🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26 May 29 - June 2 | Chicago Which trial are you watching most closely? 🌟 PLENARY GAME-CHANGERS 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer 2️⃣ LIBRETTO-432 Adjuvant selpercatinib in RET+ NSCLC 3️⃣ HARMONi-6 Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC 4️⃣ RASolute 302 Daraxonrasib (RMC-6236) in metastatic pancreatic cancer 5️⃣ SARC041 Abemaciclib in dedifferentiated liposarcoma ⚡ FRONTLINE & PERIOPERATIVE SHIFTS 6️⃣ KEYNOTE-B15 / EV-304 EV + pembrolizumab vs chemo in MIBC 7️⃣ LITESPARK-022 Pembrolizumab + belzutifan in adjuvant ccRCC 8️⃣ AMBITION Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer 9️⃣ NeoADAURA Neoadjuvant osimertinib in EGFR+ NSCLC 🔟 A-DREAM ADT interruption strategies in mCSPC 🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY 1️⃣1️⃣ DESTINY-Breast06 T-DXd expands into HER2-ultralow disease 1️⃣2️⃣ CROWN (7-year update) Lorlatinib durability in ALK+ NSCLC 1️⃣3️⃣ DeLLphi-312 Tarlatamab in frontline SCLC 1️⃣4️⃣ COMMIT Atezolizumab + FOLFOX/Bev in MSI-H mCRC 1️⃣5️⃣ IMvigor011 ctDNA-guided adjuvant atezolizumab in bladder cancer #OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers
10
162
4
383
106,759